Sapisochin G, Rodríguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez M A, Santoyo J, Castroagudín J F, Varo E, López-Andujar R, Palacios F, Sanchez Antolín G, Perez B, Guiberteau A, Blanco G, González-Diéguez M L, Rodriguez M, Varona M A, Barrera M A, Fundora Y, Ferron J A, Ramos E, Fabregat J, Ciria R, Rufian S, Otero A, Vazquez M A, Pons J A, Parrilla P, Zozaya G, Herrero J I, Charco R, Bruix J
Department of HBP Surgery and Transplantation, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain.
Am J Transplant. 2014 Mar;14(3):660-7. doi: 10.1111/ajt.12591. Epub 2014 Jan 10.
A retrospective cohort multicenter study was conducted to analyze the risk factors for tumor recurrence after liver transplantation (LT) in cirrhotic patients found to have an intrahepatic cholangiocarcinoma (iCCA) on pathology examination. We also aimed to ascertain whether there existed a subgroup of patients with single tumors ≤2 cm ("very early") in which results after LT can be acceptable. Twenty-nine patients comprised the study group, eight of whom had a "very early" iCCA (four of them incidentals). The risk of tumor recurrence was significantly associated with larger tumor size as well as larger tumor volume, microscopic vascular invasion and poor degree of differentiation. None of the patients in the "very early" iCCA subgroup presented tumor recurrence compared to 36.4% of those with single tumors >2 cm or multinodular tumors, p = 0.02. The 1-, 3- and 5-year actuarial survival of those in the "very early" iCCA subgroup was 100%, 73% and 73%, respectively. The present is the first multicenter attempt to ascertain the risk factors for tumor recurrence in cirrhotic patients found to have an iCCA on pathology examination. Cirrhotic patients with iCCA ≤2 cm achieved excellent 5-year survival, and validation of these findings by other groups may change the current exclusion of such patients from transplant programs.
开展了一项回顾性队列多中心研究,以分析在病理检查中发现患有肝内胆管癌(iCCA)的肝硬化患者肝移植(LT)后肿瘤复发的危险因素。我们还旨在确定是否存在一个单肿瘤≤2 cm的患者亚组(“极早期”),其肝移植后的结果可以接受。29例患者组成研究组,其中8例患有“极早期”iCCA(4例为偶然发现)。肿瘤复发风险与肿瘤较大尺寸、较大体积、微血管侵犯以及低分化程度显著相关。与单肿瘤>2 cm或多结节肿瘤患者的36.4%相比,“极早期”iCCA亚组中无一例患者出现肿瘤复发,p = 0.02。“极早期”iCCA亚组患者的1年、3年和5年精算生存率分别为100%、73%和73%。本研究是首次多中心尝试确定在病理检查中发现患有iCCA的肝硬化患者肿瘤复发的危险因素。iCCA≤2 cm的肝硬化患者实现了出色的5年生存率,其他研究组对这些发现的验证可能会改变目前将此类患者排除在移植项目之外的做法。